Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling

Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomized trial ELOQUENT-2 (NCT01239797). Four-year foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniwaki, Masafumi, Yoshida, Mihoko, Matsumoto, Yosuke, Shimura, Kazuho, Kuroda, Junya, Kaneko, Hiroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841936/
https://www.ncbi.nlm.nih.gov/pubmed/29531651
http://dx.doi.org/10.4084/MJHID.2018.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841936/
https://www.ncbi.nlm.nih.gov/pubmed/29531651
http://dx.doi.org/10.4084/MJHID.2018.014

Ejemplares similares